Ngā hua rapu - Tadashi Matsushita
- E whakaatu ana i te 1 - 20 hua o te 24
- Haere ki te Whārangi Whai Ake
-
1
-
2
-
3
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa mā Steven R. Lentz, S. Ehrenforth, Faraizah Abdul Karim, Tadashi Matsushita, Karin Weldingh, Jerzy Windyga, Johnny Mahlangu
I whakaputaina 2014Artigo -
4
Immunofluorescence Analysis of Neutrophil Nonmuscle Myosin Heavy Chain-A in MYH9 Disorders: Association of Subcellular Localization with MYH9 Mutations mā Shinji Kunishima, Tadashi Matsushita, Tetsuhito Kojima, Masahiro Sako, Fumihiro Kimura, Eun‐Kyeong Jo, Chikako Inoue, Tadashi Kamiya, Hidehiko Saito
I whakaputaina 2003Artigo -
5
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A mā Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
I whakaputaina 2016Artigo -
6
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors mā Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
I whakaputaina 2017Artigo -
7
Structural and functional insights into S-thiolation of human serum albumins mā Fumie Nakashima, Takahiro Shibata, Kohei Kamiya, Jun Yoshitake, Ryosuke Kikuchi, Tadashi Matsushita, Isao Ishii, Juan Antonio Giménez‐Bastida, Claus Schneider, Kôji Uchida
I whakaputaina 2018Artigo -
8
Stress Augments Insulin Resistance and Prothrombotic State mā Yasuhiro Uchida, Kyosuke Takeshita, Koji Yamamoto, Ryosuke Kikuchi, Takayuki Nakayama, Mieko Nomura, Xian Wu Cheng, Kensuke Egashira, Tadashi Matsushita, Hideo Nakamura, Toyoaki Murohara
I whakaputaina 2012Artigo -
9
Complete antithrombin deficiency in mice results in embryonic lethality mā Kazuhiro Ishiguro, Tetsuhito Kojima, Kenji Kadomatsu, Yukiko Nakayama, Akira Takagi, Misao Suzuki, Naoki Takeda, Masafumi Ito, Koji Yamamoto, Tadashi Matsushita, Kazuo Kusugami, Takashi Muramatsu, Hidehiko Saito
I whakaputaina 2000Artigo -
10
Syndecan-4 Deficiency Leads to High Mortality of Lipopolysaccharide-injected Mice mā Kazuhiro Ishiguro, Kenji Kadomatsu, Tetsuhito Kojima, Hisako Muramatsu, Mitsunori Iwase, Yasunobu Yoshikai, Masamitsu Yanada, Koji Yamamoto, Tadashi Matsushita, Masahiko Nishimura, Kazuo Kusugami, Hidehiko Saito, Takashi Muramatsu
I whakaputaina 2001Artigo -
11
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis mā Bethany Samuelson Bannow, Michael Recht, Claude Négrier, Cédric Hermans, Erik Berntorp, Hermann Eichler, Maria Elisa Mancuso, Robert Klamroth, Jamie O’Hara, Elena Santagostino, Tadashi Matsushita, Craig M. Kessler
I whakaputaina 2019Revisão -
12
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial mā Peter W. Collins, Guy Young, Karin Knobe, Faraizah Abdul Karim, Pantep Angchaisuksiri, Claus Banner, Türkiz Gursel, Johnny Mahlangu, Tadashi Matsushita, Eveline P. Mauser‐Bunschoten, Johannes Oldenburg, Christopher Walsh, Claude Négrier
I whakaputaina 2014Artigo -
13
Thrombosis from a Prothrombin Mutation Conveying Antithrombin Resistance mā Yuhri Miyawaki, Atsuo Suzuki, Junko Fujita, Asuka Maki, Eriko Okuyama, Moe Murata, Akira Takagi, Takashi Murate, Shinji Kunishima, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tomoki Naoe, Hidehiko Saito, Tetsuhito Kojima
I whakaputaina 2012Artigo -
14
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice mā Maimaiti Yisireyili, Motoharu Hayashi, Hongxian Wu, Yasuhiro Uchida, Koji Yamamoto, Ryosuke Kikuchi, Mohammad Shoaib Hamrah, Takayuki Nakayama, Xian Wu Cheng, Tadashi Matsushita, Shigeo Nakamura, Toshimitsu Niwa, Toyoaki Murohara, Kyosuke Takeshita
I whakaputaina 2017Artigo -
15
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results mā Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Víctor Jiménez‐Yuste, Kaan Kavaklı, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić‐Šalek, Johannes Oldenburg
I whakaputaina 2019Artigo -
16
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors mā Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Víctor Jiménez‐Yuste, Kaan Kavaklı, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić‐Šalek, Johannes Oldenburg, Pratima Chowdary
I whakaputaina 2022Artigo -
17
Identification of six novel MYH9 mutations and genotype–phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions mā Shinji Kunishima, Tadashi Matsushita, Toshiya Kojima, N Amemiya, Y. M. Choi, Naoki Hosaka, M. Inoue, Jung Yh, S Mamiya, Kiyoshi Matsumoto, Yuji Miyajima, Guolong Zhang, Changgeng Ruan, Kazuto Saito, K S Song, H.-J. Yoon, T. Kamiya, Hajime Saito
I whakaputaina 2001Artigo -
18
International consensus recommendations on the management of people with haemophilia B mā Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d’Oiron, Cédric Hermans, Víctor Jiménez‐Yuste, Adriana Linares, Tadashi Matsushita, Simon McRae, Margareth C. Ozelo, Sean Platton, Darrel W. Stafford, Robert F. Sidonio, Andreas Tiede
I whakaputaina 2022Revisão -
19
An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease mā Ryosuke Kikuchi, Kazuto Nakamura, Susan MacLauchlan, Doan Thi-Minh Ngo, Ippei Shimizu, José J. Fuster, Yasufumi Katanasaka, Sumiko Yoshida, Yan Qiu, Terry P. Yamaguchi, Tadashi Matsushita, Toyoaki Murohara, Noyan Gokce, David O. Bates, Naomi M. Hamburg, Kenneth Walsh
I whakaputaina 2014Artigo -
20
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extensio... mā John Pasi, Kathelijn Fischer, Margaret V. Ragni, Roshni Kulkarni, Margareth C. Ozelo, Johnny Mahlangu, Amy D. Shapiro, Stephanie P’ng, Hérvè Chambost, Beatrice Nolan, Carolyn M. Bennett, Tadashi Matsushita, Bent Winding, Joachim Fruebis, Huixing Yuan, Dan Rudin, Johannes Oldenburg
I whakaputaina 2020Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Internal medicine
Immunology
Biology
Gene
Biochemistry
Surgery
Chemistry
Clinical trial
Endocrinology
Platelet
Antibody
Genetics
Pediatrics
Clinical endpoint
Factor IX
Haemophilia
Haemophilia A
Recombinant DNA
Amino acid
Antithrombin
Cell biology
Coagulation
Enzyme
Gastroenterology
Haemophilia B
Heparin
Thrombin
Von Willebrand factor
Adverse effect